title: Clinical experience with the use of daptomycin in a tertiary care teaching hospital in Barcelona, Spain.
abstract: OBJECTIVE
  We reviewed the clinical use of daptomycin in daily practice.
  
  
  METHODS
  Efficacy and safety were assessed in 175 consecutive patients given daptomycin for at least 72 h.
  
  
  RESULTS
  Daptomycin was given as rescue treatment in 50.9% of cases. Bloodstream infection (34.8%) and skin/soft-tissue infection (19.4%) were the most frequent. In 62.3% of patients, the dose of ≤ 6 mg/kg/day was administered. Staphylococcus spp. were isolated in 52.6% of cases (MRSA in 9.5%, CoNS in 34.3%) and Enterococcus spp. in 8.7%. Clinical success was 75% and microbiological eradication 48.6%. Two patients discontinued daptomycin due to hemolytic anemia of unlikely and possible relationship with daptomycin, respectively.
  
  
  CONCLUSIONS
  Daptomycin was effective and well tolerated in patients with severe Gram-positive infections.
authors.affiliation: Department of Infectious Diseases, Hospital del Mar, Barcelona, Spain.
authors.forename: Nancy
authors.initials: N
authors.lastname: Sandoval
authors.affiliation: Department of Pharmacy, Hospital del Mar, Barcelona, Spain.|Universitat Autònoma de Barcelona, Barcelona, Spain.
authors.forename: Santiago
authors.initials: S
authors.lastname: Grau
authors.affiliation: Department of Infectious Diseases, Hospital del Mar, Barcelona, Spain.
authors.forename: Luisa
authors.initials: L
authors.lastname: Sorlí
authors.affiliation: Department of Infectious Diseases, Hospital del Mar, Barcelona, Spain.
authors.forename: Milagro
authors.initials: M
authors.lastname: Montero
authors.affiliation: Department of Infectious Diseases, Hospital del Mar, Barcelona, Spain.
authors.forename: Erika
authors.initials: E
authors.lastname: Esteve
authors.affiliation: Department of Infectious Diseases, Hospital del Mar, Barcelona, Spain.
authors.forename: Juan Pablo
authors.initials: JP
authors.lastname: Horcajada
mesh_terms: D000368:Aged; D000743:Anemia, Hemolytic / Q000175:diagnosis / Q000209:etiology; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D016470:Bacteremia / Q000188:drug therapy / Q000382:microbiology; D017576:Daptomycin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D016983:Enterococcus / Q000302:isolation & purification; D005260:Female; D016908:Gram-Positive Bacterial Infections / Q000188:drug therapy* / Q000382:microbiology; D006784:Hospitals, Teaching; D006801:Humans; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D013030:Spain; D013210:Staphylococcus / Q000302:isolation & purification; D063128:Tertiary Health Care; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000900:Anti-Bacterial Agents; D017576:Daptomycin
keywords: Gram-positive infections; bacteremia; clinical outcome; daptomycin; retrospective study